Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.

Bpifrance

European Innovation Council

Anaxago

Meusinvest (Noshaq)

Cédric Delorme

Osivax

OSIVAX is a biotechnology company specializing in the development of vaccines and immunotherapies. The company leverages its proprietary technology platforms to design and produce vaccines aimed at preventing and treating infectious diseases, cancers, and autoimmune conditions.

COM:OSIVAX

OSIVAX

Filings Not Available